NCT05369312View on ClinicalTrials.gov

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2025

Conditions
Solid TumorNon-small Cell Lung CancerPancreatic CancerColorectal Cancer
Interventions
DRUG

BPI-442096

Subjects will receive BPI-442096 until disease progression

Trial Locations (5)

200032

Zhongshan Hospital affiliated to Fudan University, Xuhui

310004

Zhejiang Cancer Hospital, Hangzhou

453100

Henan Tumor Hospital, Zhengzhou

510080

Guangdong Provincial People's Hospital, Guangzhou

The First Affiliated Hospital of Sun yat-sen university, Guangzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY